August 2012
-
Optinose announced that it has signed an agreement with Kaleo for co-promotion of Optinose’s Xhance fluticasone propionate nasal spray for the treatment of nasal polyps. Xhance was approved by the FDA for that indication in… Read more . . .
-
Vienna-based biotech incubator CEBINA (Central European Biotech Incubator and Accelerator) said that in vitro testing has shown that azelastine has anti-SARS-CoV-2 activity, and the company is discussing possible development and production of an azelastine nasal spray for the… Read more . . .
-
Altimmune said that it has signed an agreement with DynPort Vaccine Company regarding Altimmune’s AdCovid intranasal vaccine candidate for COVID-19. The company announced in March 2020 that it had partnered with the University of Alabama Birmingham to… Read more . . .
-
Iconovo announced that BNC Korea has acquired rights to manufacture and market generic versions of Ultibro indacaterol/glycopyrronium and Seebri glycopyrronium DPIs based on Iconovo formulations and the company’s ICOcap device. The deal covers a territory… Read more . . .
-
Lonza Pharma & Biotech has established a new Center of Excellence for DPI development at its location in Bend, OR, USA, the company said. The site originally belonged to spray drying specialist Bend Research, which was… Read more . . .
-
Medical propellant maker Koura announced that it has donated 10,000 MDIs to the government of the Indian state of Maharashtra to help meet the demand for inhalers during the COVID-19 pandemic. Specifically, the company said… Read more . . .
-
Inhalation contract R&D company iPharma Labs has announced the introduction of new GMP testing services for testing and development of OINDPs, including inhaled drugs for the treatment of COVID-19. The company also announced the addition… Read more . . .
-
Novartis’s Enerzair Breezhaler (QVM149) indacaterol / glycopyrronium / mometasone furoate DPI has been approved by the EC for the treatment of asthma, the company said. The inhaler can now be marketed with an optional Propeller… Read more . . .
-
Chinese OINDP developer CF PharmTech announced that it has completed a $50 million Series F financing round approximately six months after completing a $90 million financing round. Investors participating in the latest financing include BioTrack Capital,… Read more . . .
-
Dutch inhaled drug developer PureIMS said that it has initiated a Phase 1 clinical trial of its Amikacin Cyclops DPI, which it is developing for the treatment of drug susceptible tuberculosis. The single ascending dose… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.